Skip to main content
. 2019 Dec 27;11(12):422–432. doi: 10.4240/wjgs.v11.i12.422

Table 3.

Comparative analysis of variables changes between baseline and 72 h after treatment

Patients PMX-HP (n = 20)
Control (n = 20)
P value
To1 T722 To3 T724
SOFA score 11.2 ± 5.8 4.7 ± 3.5 10.0 ± 4.0 8.7 ± 7.3 0.047a
Respiratory SOFA 2.6 ± 1.0 1.9 ± 1.0 2.6 ± 1.5 1.8 ± 1.0 0.799
Cardiovascular SOFA 3.4 ± 1.2 0.4 ± 0.9 2.3 ± 1.8 1.2 ± 1.3 0.072
Liver SOFA 0.7 ± 0.9 1.1 ± 1.5 0.7 ± 1.3 1.4 ± 1.3 0.683
Renal SOFA 2.6 ± 1.0 0.7 ± 1.0 2.6 ± 1.5 2.8 ± 1.6 0.000a
Coagulation SOFA 1.6 ± 1.5 1.3 ± 1.3 1.2 ± 1.2 2.8 ± 1.8 0.014a
WBC, 109/L 87.7 ± 65.0 102.5 ± 62.7 94.0 ± 49.1 115.6 ± 59.0 0.552
Hb, g/L 9.6 ± 2.0 9.0 ± 0.9 10.5 ± 2.2 9.7 ± 1.0 0.024a
Inotropic score 163.7 ± 302.1 8.9 ± 19.1 90.8 ± 181.7 1.4 ± 4.2 0.006a
VDI 2.4 ± 3.4 0.1 ± 0.3 1.0 ± 2.0 0.0 ± 0.1 0.001a
1

Immediately after completion of two session of polymyxin B hemoperfusion (PMX-HP);

2

Seventy-two hours after completion of two session of PMX-HP;

3

Immediately after surgical control;

4

Seventy-two hours after conventional standard therapy according to survival sepsis campaign.

a

P < 0.05, compared with variables between just before initiating treatment and 72 h after initiating the treatment in PMX-HP group and control group. SOFA: Sequential organ failure assessment; WBC: White blood cell; Hb: Hemoglobin; VDI: Vasopressor dependency index; PMX-HP: Polymyxin B hemoperfusion.